Sobi enters partnership with Tigenix for the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Sobi enters partnership with Tigenix for the commercialisation of ChondroCelect

Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company has acquired the licencing rights to market and distribute ChondroCelect, a cell- based medicinal product for the repair of cartilage defects of the knee, from TiGenix NV (Euronext Brussels: TIG). ChondroCelect was the first cell-based product to be approved in Europe. It is currently available for patients and reimbursed in Belgium, the Netherlands and Spain. Sobi will continue to market and distribute the product where it is currently available and will work to expand the product's availability to patients in a much wider area, including the rest of the European Union, Norway, Russia, Switzerland, Turkey, and the countries in the Middle East and North Africa. "We are delighted to reach this agreement with Sobi", said Eduardo Bravo, CEO of Tigenix. "With their experience of marketing and distributing specialty products Sobi has the ability to bring ChondroCelect to a far greater number of patients in many more countries." "ChondroCelect is an exciting therapy, and we are proud to expand our offering to orthopaedic patients," said Anders Edvell, MD, PhD, and Vice President Sobi Partner Products. "This partnership is an excellent fit with Partner Products' strategy for achieving sustainable patient access to new and innovative treatments with a pan-European scope." --- About ChondroCelect ChondroCelect, indicated for cartilage repair in the knee, is a cell-based medicinal product for use in autologous chondrocyte implantation in which cells are taken from the patient's own knee, multiplied to reach a large quantity, and then re-implanted at the site of the defect. About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with three late stage biological development projects within Haemophilia and Neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. About Sobi Partner Products Sobi Partner Products (SPP) is a business unit within Sobi which offers a unique commercial platform for partners with niche and specialty products. SPP provides extensive knowledge and local experience through our direct presence across EU, Eastern Europe, Russia, Middle East and North Africa. We apply an integrated commercial, medical, and market access approach to products which address important unmet needs, spanning from named patient use (NPU) programs, through to reimbursement and full commercialization, primarily in the Centre of Expertise setting. For more information please contact Media relations Oskar Bosson, Head of Communications T: +46 70 410 71 80 oskar.bosson@sobi.com Investor relations Jörgen Winroth, Vice President, Head of Investor Relations T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 jorgen.winroth@sobi.com [HUG#1774000]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

APP Group's New Conservation Efforts in Sumatra

Updated Category News Views 215

Taking a Bold Step Towards Conservation APP Group, in collaboration with Proforest, WWF-Indonesia, and KKI WARSI, is setting its sights on a more sustainable future with the PROTECT30 initiative. This isn't just another dime-a-dozen CSR project—it’s a concerted effort aimed at conserving Sumatra's precious Bukit Tigapuluh landscape. These folks are playing the long...

Continue Reading
Sussex County Data Breach Raises Security Concerns

Updated Category News Views 136

The Digital Fiasco: A Wake-Up Call Straight out of Sussex County in good ol' New Jersey, we’re staring down another data breach, folks. When you hear about a data privacy incident, there's always that same sinking feeling of another layer of personal security peeled away. This time, the Sussex County Prosecutor's Office got caught in the crossfire, with personal info...

Continue Reading
Future FinTech Under Investigation: Shareholder Impact Looms

Updated Category News Views 81

Future FinTech Faces Legal Scrutiny When the walls close in under financial suspicion, the spotlight can burn brighter than any anticipated market gain. That's precisely what Future FinTech Group Inc. (NasdaqCM: FTFT) is up against now. Kahn Swick & Foti, LLC, featuring the ex-Attorney General of Louisiana, Charles C. Foti, Jr., has begun scrutinizing the actions of...

Continue Reading
New Frontiers in Glaucoma Care: Less Drops Required?

Updated Category News Views 88

Eyeing New Glaucoma Treatment Strategies You think glaucoma treatment is all about popping eye drops day in and day out? Well, turns out, things are shifting down in Racine, Wisconsin. Folks at HelloNation have been spilling the beans on earlier glaucoma interventions that might just lighten your load of daily medications. Doctors I. Paul Singh and R. Krishna Sanka...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 143

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 77

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
212NYC Gala Celebrates Ad Industry's Human Touch

Updated Category News Views 208

The Advertising Gala with Heart When you toss nearly 300 advertising honchos into a room at Tribeca's Rooftop, you don't just get another bash; you get an industry checkpoint. This time, the 212NYC shindig on November 5, 2026, wasn't just about stroking egos. It was about spotlighting the soul in business, right when AI threatens to run wild with it. Navigating AI's...

Continue Reading
Madrigal Faces Legal Scrutiny Amid Whistleblower Claims

Updated Category News Views 204

The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 63

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Aurora Innovation Faces Legal Heat Amid Delays

Updated Category News Views 76

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Continue Reading

Top 5 Most Recently Viewed Articles

Pedro Langa Takes the Helm as Indigo Ag's New CFO

Updated Category News Views 351

Pedro Langa Appointed Chief Financial Officer at Indigo Ag Indigo Ag has named Pedro Langa as its new Chief Financial Officer, effective immediately. This decision follows an extensive recruitment process that aimed to find the best fit for this vital role. Langa comes with over two decades of experience in finance across various sectors, particularly in food and...

Continue Reading
Vuzix Corporation Achieves Historic Milestone with VUZI Stock

Updated Category News Views 304

Vuzix Corporation Stocks Hit New Heights Vuzix Corporation (NASDAQ: VUZI) has recently made headlines by reaching a remarkable 52-week high, peaking at $3.97. This achievement signals a strong market confidence in the company, as the stock has realized an impressive 188.72% return over the past six months. Despite the surge, it remains crucial to navigate the analysis...

Continue Reading
Dogecoin Rises as Bitcoin Stabilizes; Analysts Eye $90K Soon

Updated Category News Views 189

Bitcoin's Roller Coaster and Dogecoin's Surge The cryptocurrency market is always buzzing, and recently, Bitcoin has paused its rally, attracting significant interest as it hovers just above $67,000. The king of meme coins, Dogecoin, on the other hand, has seen a remarkable rise, with its value increasing over 7% in a single day. Recent Performance of Major...

Continue Reading
Nokia Corporation's Significant Share Repurchase Initiative

Updated Category News Views 140

Nokia Corporation's Strategic Share Repurchase Plan Nokia Corporation is taking bold steps to strengthen its market position and boost shareholder value through a proactive share repurchase program. This initiative signifies Nokia's commitment to managing its stock efficiently while providing returns to its investors. Details of the Share Repurchase Recently, Nokia...

Continue Reading
Innovative Investment Fuels Okika Devices' Future Growth Strategy

Updated Category News Views 222

Strategic Investment Boosts Okika Devices Advancement Colorado ONE Fund, which is part of the ONE Funds initiative, has made a major investment in Okika Devices, a company recognized for its innovation in Field Programmable Analog Array (FPAA) technology. This investment aligns with Colorado ONE Fund's mission to support technologies that advance the local innovation...

Continue Reading